drugset / Trial / NCT00690378

Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections

NCT00690378

Phase 2 Completed 137 enrolled Pfizer
RandomizedParallel-groupSingle-blindTreatment

Summary

The purpose of this study is to determine whether NXL104 plus ceftazidime is effective in the treatment of complicated urinary tract infections as compared to a comparator group.

Timeline

Start
2008-11
Primary completion
2010-06
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Ceftazidime Small molecule 500 mg Intravenous
Comparator Imipenem/Cilastatin Unknown 500 mg
Subject avibactam Small molecule 125 mg Intravenous